Comparative Pharmacology
Head-to-head clinical analysis: MIDAZOLAM HYDROCHLORIDE versus SERAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDAZOLAM HYDROCHLORIDE versus SERAX.
MIDAZOLAM HYDROCHLORIDE vs SERAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine agonist at GABA-A receptors, enhancing chloride influx and neuronal hyperpolarization, leading to anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
SERAX (oxazepam) is a benzodiazepine that modulates GABA-A receptors, enhancing the inhibitory effect of GABA, leading to anxiolytic, sedative, and anticonvulsant effects.
Adults: IV: 0.5-2 mg slow IV over 2 minutes, may repeat q2-3min; IM: 0.07-0.08 mg/kg (usual total 2-3 mg); oral: 7.5-15 mg once. For sedation, titrate to effect.
Oral: 5-10 mg twice daily; maximum 20 mg/day. Intravenous: 2-5 mg slow IV push, may repeat after 2 hours.
None Documented
None Documented
Terminal elimination half-life: 1.5-3.5 hours (range 1-12 hours) in healthy adults; prolonged in elderly (5-6 hours), obese, hepatic impairment (up to 20 hours), and critical illness (up to 12 hours). Context: short-acting benzodiazepine; half-life supports use for procedural sedation and ICU sedation, but accumulation can occur with prolonged infusions.
Terminal elimination half-life is 8-15 hours (mean 12 hours) in adults; prolonged in renal impairment.
Renal: <1% unchanged; hepatic metabolism to 1-hydroxymidazolam (active) and other metabolites, excreted primarily in urine (60-80%) as glucuronide conjugates, and about 2-10% in feces.
Primarily renal (urinary) as unchanged drug (60-80%) and metabolites (20-40%); less than 5% fecal elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine